ArticleOncoTargets and therapy2016
Downregulation of ALDOB is associated with poor prognosis of patients with gastric cancer.
Article in OncoTargets and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- Meta-Analysis Reveals the Prognostic Relevance of Nuclear and Membrane-Associated Bile Acid Receptors in Gastric Cancer.Clinical and translational gastroenterology · 2021Pooled it
- Utility of GDF-15 as a diagnostic biomarker in gastric cancer: an investigation combining GEO, TCGA and meta-analysis.FEBS open bio · 2019Pooled it
- Review
- FNDC1 Competitively Binds Gβ2 to Suppress the β-Catenin-Destruction Complex and Promote Gastric Cancer Malignancy.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- CHI3L1: a key driver in gastritis-to-cancer transformation.Journal of translational medicine · 2025Article
- SUV39H1 Regulates Gastric Cancer Progression via the H3K9me3/ALDOB Axis.Cell biochemistry and biophysics · 2025Article
- Quercetin Inhibits Gastric Cancer Progression via FAM198B/MAPK Pathway Modulation.Pharmacogenomics and personalized medicine · 2025Article
- Identification and validation of tumor microenvironment-related therapeutic targets in gastric cancer using integrated multi-omics and molecular docking approaches.Frontiers in bioinformatics · 2025Article
- ALDOB is a prognostic biomarker and a potential immunotherapy target for clear cell renal cell carcinoma.PeerJ · 2025Article
- AMPK-regulated glycerol excretion maintains metabolic crosstalk between reductive and energetic stress.Nature cell biology · 2025Article
- Fructose-1, 6-Bisphosphate Aldolase B Suppresses Glycolysis and Tumor Progression of Gastric Cancer.Digestive diseases and sciences · 2024Article
- Functional Profiling of Soft Tissue Sarcoma Using Mechanistic Models.International journal of molecular sciences · 2023Article
- Protein Biomarker Discovery Studies on Urinary sEV Fractions Separated with UF-SEC for the First Diagnosis and Detection of Recurrence in Bladder Cancer Patients.Biomolecules · 2023Article
- Predictive Value of Gene Databases in Discovering New Biomarkers and New Therapeutic Targets in Lung Cancer.Medicina (Kaunas, Lithuania) · 2023Article
- Dysregulation of core neurodevelopmental pathways-a common feature of cancers with perineural invasion.Frontiers in genetics · 2023Article
- ALDOB plays a tumor-suppressive role by inhibiting AKT activation in gastric cancer.Journal of Cancer · 2023Article
- Protection of c-Fos from autophagic degradation by PRMT1-mediated methylation fosters gastric tumorigenesis.International journal of biological sciences · 2023Article
- Identification of significant genes associated with prognosis of gastric cancer by bioinformatics analysis.Journal of the Egyptian National Cancer Institute · 2022Article
- H19 may regulate the immune cell infiltration in carcinogenesis of gastric cancer through miR-378a-5p/SERPINH1 signaling.World journal of surgical oncology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo examine the expression of ALDOB in gastric cancer (GC) tissue and to reveal its potential clinicopathological and prognostic significance. MATERIALS AND
methodsWe screened for genes that were differentially expressed between GC and nontumor tissues using a microarray, specifically the Affymetrix U133 Plus 2.0 Array platform. We then verified the transcriptional and translational levels of ALDOB by performing quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC). In addition, a merged data set based on the Gene Expression Omnibus was generated and a survival analysis performed.
resultsThe microarray analysis revealed that
conclusionThe expression of ALDOB in GC tissue was significantly related to the clinicopathological features and prognosis of the disease, thus suggesting that ALDOB could act as a novel molecular marker for GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.